Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0054-01 55513-0054 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct 1, 2001 Dec 31, 2008 No Longer Used
55513-0021-04 55513-0021 Darbepoetin alfa Aranesp 40.0 ug/.4mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 14, 2006 In Use
55513-0023-01 55513-0023 Darbepoetin alfa Aranesp 60.0 ug/.3mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Feb 18, 2011 In Use
55513-0048-01 55513-0048 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb 10, 2004 Feb 28, 2009 No Longer Used
55513-0011-04 55513-0011 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Oct 1, 2001 Nov 30, 2008 No Longer Used
55513-0002-01 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sep 11, 2006 In Use
55513-0025-01 55513-0025 Darbepoetin alfa Aranesp 100.0 ug/.5mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Feb 18, 2011 In Use
55513-0025-04 55513-0025 Darbepoetin alfa Aranesp 100.0 ug/.5mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug 14, 2006 In Use
50419-0395-72 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Mar 3, 2021 In Use
50419-0395-01 50419-0395 Darolutamide Nubeqa 300.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Jul 31, 2019 In Use
68001-0663-04 68001-0663 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 29, 2025 In Use
00003-0852-11 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 3, 2009 Jan 26, 2011 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
70709-0156-14 70709-0156 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
59651-0544-60 59651-0544 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
66993-0237-30 66993-0237 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
59651-0547-30 59651-0547 DASATINIB DASATINIB 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
00480-5104-56 00480-5104 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
00480-5102-06 00480-5102 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
66993-0235-60 66993-0235 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
00480-5103-06 00480-5103 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 18, 2025 In Use
70377-0087-11 70377-0087 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
70709-0151-20 70709-0151 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 22, 2025 In Use
59651-0543-60 59651-0543 DASATINIB DASATINIB 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use

Found 12159 results — Export these results